Director Han Yusheng adds 314,870 Burning Rock Biotech (BNR) shares

Q: What insider transaction did Han Yusheng report at Burning Rock Biotech (BNR)?

Director Han Yusheng reported an open-market purchase of 314,870 shares of Burning Rock Biotech. The shares were bought at a weighted average price of $17.36, indicating he chose to increase his direct ownership using personal capital rather than receiving stock-based compensation.

Q: How many Burning Rock Biotech (BNR) shares does Han Yusheng hold after this trade?

Following the reported purchase, Han Yusheng directly owns 17,672,676 shares of Burning Rock Biotech. This post-transaction figure, disclosed in the filing, highlights that he maintains a substantial equity position in the company after increasing his holdings through the open-market buy.

Q: What type of security did Han Yusheng buy in the Burning Rock Biotech (BNR) Form 4?

The transaction involved Ordinary Shares represented by American depositary shares . A footnote explains that one American depositary share corresponds to ten Class A ordinary shares, providing international investors a way to trade the company’s equity through depositary receipts rather than the underlying local shares directly.

Q: Was Han Yusheng’s Burning Rock Biotech (BNR) trade an open-market purchase?

Yes. The Form 4 characterizes the transaction as an open-market purchase , coded as a “P” transaction. This means the director bought the shares in the market or a private transaction, rather than receiving them via grants, options exercises, or other non-market equity compensation mechanisms.

Filing Impact

(Very High)

Filing Sentiment

(Very Positive)

Form Type

Rhea-AI Filing Summary

Burning Rock Biotech Ltd director Han Yusheng bought 314,870 shares in an open-market purchase. The shares were acquired at a weighted average price of $17.36 per share, across multiple trades between $16.10 and $18.99. Following this transaction, he directly owns 17,672,676 shares, reflecting a significant ongoing stake in the company.

Insights

Director Han increased his direct stake with a sizable open-market buy.

Director Han Yusheng executed an open-market purchase of 314,870 Burning Rock Biotech shares at a weighted average price of $17.36. Open-market purchases generally signal deliberate commitment, since the insider is using cash to increase exposure rather than receiving shares as compensation.

After the trade, Han directly holds 17,672,676 shares, indicating a large continuing position. The filing notes the price reflects multiple trades between $16.10 and $18.99, suggesting he was accumulating over a range rather than a single print, but the broader impact depends on the company’s total shares outstanding.

Insider Trade Summary

Net Buyer: 314,870 shares ($5,466,143)

Net Buy 1 txn

Insider Han Yusheng

Role Director

Bought 314,870 shs ($5.47M)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares (represented by American depositary shares)	314,870	$17.36	$5.47M

Holdings After Transaction: Ordinary Shares (represented by American depositary shares) — 17,672,676 shares (Direct)

Footnotes (1)

One American depositary share represents ten Class A ordinary shares. The price reported is the weighted average price of American depositary shares. These American depositary shares were purchased in multiple transactions at prices ranging from $16.10 to $18.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 314,870 shares Weighted average price: $17.36 per share Post-transaction holdings: 17,672,676 shares +2 more

5 metrics

Shares purchased 314,870 shares Open-market purchase on March 31, 2026

Weighted average price $17.36 per share Price for the purchased shares

Post-transaction holdings 17,672,676 shares Shares directly owned after the transaction

Trade price range $16.10–$18.99 per share Range of prices across multiple purchase trades

ADS to ordinary share ratio 1 ADS : 10 Class A ordinary shares Relationship between ADS and underlying ordinary shares

Key Terms

American depositary shares, Class A ordinary shares, weighted average price, open-market purchase

4 terms

American depositary shares financial

"Ordinary Shares (represented by American depositary shares)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Class A ordinary shares financial

"One American depositary share represents ten Class A ordinary shares."

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

weighted average price financial

"The price reported is the weighted average price of American depositary shares."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 07:17 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Han Yusheng

(Last)

(First)

(Middle)

NO. 46 - 2000 JIANHE ROAD

(Street)

SHANGHAI

CHINA

200336

(City)

(State)

(Zip)

CHINA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Burning Rock Biotech Ltd [ BNR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares (represented by American depositary shares)⁽¹⁾	03/31/2026		P		314,870	A	$17.36⁽²⁾	17,672,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. One American depositary share represents ten Class A ordinary shares.

2. The price reported is the weighted average price of American depositary shares. These American depositary shares were purchased in multiple transactions at prices ranging from $16.10 to $18.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Yuheng Huang, Attorney-in-Fact for Yusheng Han	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Han Yusheng report at Burning Rock Biotech (BNR)?

Director Han Yusheng reported an open-market purchase of 314,870 shares of Burning Rock Biotech. The shares were bought at a weighted average price of $17.36, indicating he chose to increase his direct ownership using personal capital rather than receiving stock-based compensation.

At what prices did Burning Rock Biotech (BNR) shares trade in Han Yusheng’s purchase?

The reported transaction used a weighted average price of $17.36 per share. According to the disclosure, the shares were purchased in multiple trades with prices ranging from $16.10 to $18.99, reflecting accumulation across a trading range rather than a single execution.

How many Burning Rock Biotech (BNR) shares does Han Yusheng hold after this trade?

Following the reported purchase, Han Yusheng directly owns 17,672,676 shares of Burning Rock Biotech. This post-transaction figure, disclosed in the filing, highlights that he maintains a substantial equity position in the company after increasing his holdings through the open-market buy.

What type of security did Han Yusheng buy in the Burning Rock Biotech (BNR) Form 4?

The transaction involved Ordinary Shares represented by American depositary shares. A footnote explains that one American depositary share corresponds to ten Class A ordinary shares, providing international investors a way to trade the company’s equity through depositary receipts rather than the underlying local shares directly.

Was Han Yusheng’s Burning Rock Biotech (BNR) trade an open-market purchase?

Yes. The Form 4 characterizes the transaction as an open-market purchase, coded as a “P” transaction. This means the director bought the shares in the market or a private transaction, rather than receiving them via grants, options exercises, or other non-market equity compensation mechanisms.